Insulet Corporation (PODD)

Market Cap	19.15B
Revenue (ttm)	2.07B
Net Income (ttm)	418.30M
Shares Out	70.23M
EPS (ttm)	5.78
PE Ratio	47.15
Forward PE	65.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	880,403
Open	273.18
Previous Close	274.04
Day's Range	268.83 - 276.13
52-Week Range	160.19 - 289.46
Beta	1.29
Analysts	Buy
Price Target	294.65 (+8.07%)
Earnings Date	May 8, 2025

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is cont...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 15, 2007
• Employees: 3,900
• Stock Exchange: NASDAQ
• Ticker Symbol: PODD
• Website: https://www.insulet.com

Financial Performance

In 2024, Insulet's revenue was $2.07 billion, an increase of 22.07% compared to the previous year's $1.70 billion. Earnings were $418.30 million, an increase of 102.76%.

Analyst Forecast

According to 17 analysts, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $294.65, which is an increase of 8.07% from the latest price.

Price Target

$294.65

(8.07% upside)

Analyst Consensus: Buy